At a forward price-to-earnings ratio of 10.8 times, the share is moving higher from it's lowest valuation levels since coming to market. The last set of results were mixed with Prescription turnover increasing 0.7%, consumer turnover rising by 13.4% to R892m, Hospital turnover improving by 11.9% while gross margins decreased from 39.4% to 37.3%. Group Revenue increased by 4%, Operating Expenditure decreased by 2%, Headline Earnings increased by +1% and Headline Earnings Per Share at 417.5 cents. Growth: adversely impacted by the in the fourth quarter of the financial year, by the virtual absence of a cold and flu season in South Africa, resulting in very few orders for replenishment of the winter basket. While the group stated that it is in a strong financial position and that it generated strong cash flows in FY2020, no dividend was declared as the board decided to adopt a prudent approach and preserve cash until the full impact of COVID-19 is better understood. Reviewing the monthly share price chart, we note the price continuing to rebound off the monthly trend linie support extending back to the swing lows of October-2008 and March-2016. In addition, the daily chart also sees the price clearing it's 200-day moving average - a key technical development. The pivot/clearance level is a close above 4818c however aggressive traders could look to purchase at current levels using a stop-loss of 4170c. Upside Targets are 5228c, 5730c.